Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the best dose of mibefradil dihydrochloride when given together with temozolomide in treating patients with glioma.
Key facts
- Study ID
- NCT01480050
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 28
- Starts
- 2012-05-31
- Expected to finish
- 2017-06-01
- Last updated by the study team
- 2019-05-22
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UAB Comprehensive Cancer Center — Birmingham, Alabama, United States
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
- Johns Hopkins University — Baltimore, Maryland, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.